In its assessment at the beginning of 2022, the SCCS was unable to reach a conclusion on the safety of prostaglandin analogues substances. Since the industry has provided new data, the Scientific Committee has just published a new preliminary Opinion. It is open for comments until 18 August 2025.
Background
In the Opinion SCCS/1635/21, the SCCS was not able to conclude on the safety of “Isopropyl Cloprostenate” and “Ethyl Tafluprostamide” in cosmetic products in view of the limited data provided and the available information in published literature.
By January 2024, industry submitted additional evidence to support the safe use of “Ethyl Tafluprostamide” (DDDE), “Methylamido-Dihydro-Noralfaprostal” (MDN) and “Isopropyl Cloprostenate” (IPCP) in eyelash and eyebrow products.
For an exhaustive background information, see the article
• Prostaglandin analogues: new request for Opinion to SCCS, CosmeticOBS, 9 April 2024
The SCCS Opinion
(1) In light of the data provided and taking under consideration the concerns raised by the SCCS in Opinion SCCS/1635/21,
(a) does the SCCS consider Ethyl Tafluprostamide safe when used in eyelash and eyebrow products up to a maximum concentration of 0.018 %?
(b) does the SCCS consider Methylamido-Dihydro-Noralfaprostal safe when used in eyelash and eyebrow products up to a maximum concentration of 0.03 %?
(c) does the SCCS consider Isopropyl Cloprostenate safe when used in eyelash and eyebrow products up to a maximum concentration of 0.005 %?
Having evaluated all the evidence provided by the Applicants to support the safe …
